- Home
- OMH vs CDT Comparison
OMH vs CDT Comparison
Compare OMH & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- CDT
- Stock Information
- Founded
- OMH 2015
- CDT 2019
- Country
- OMH Singapore
- CDT United States
- Employees
- OMH N/A
- CDT N/A
- Industry
- OMH Real Estate
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- CDT Health Care
- Exchange
- OMH Nasdaq
- CDT Nasdaq
- Market Cap
- OMH N/A
- CDT 5.2M
- IPO Year
- OMH 2023
- CDT N/A
- Fundamental
- Price
- OMH $2.55
- CDT $0.69
- Analyst Decision
- OMH Strong Buy
- CDT
- Analyst Count
- OMH 1
- CDT 0
- Target Price
- OMH $15.00
- CDT N/A
- AVG Volume (30 Days)
- OMH 17.0K
- CDT 1.4M
- Earning Date
- OMH 01-01-0001
- CDT 05-13-2025
- Dividend Yield
- OMH N/A
- CDT N/A
- EPS Growth
- OMH N/A
- CDT N/A
- EPS
- OMH N/A
- CDT N/A
- Revenue
- OMH $5,390,607.00
- CDT N/A
- Revenue This Year
- OMH $111.47
- CDT N/A
- Revenue Next Year
- OMH $32.08
- CDT N/A
- P/E Ratio
- OMH N/A
- CDT N/A
- Revenue Growth
- OMH 25.77
- CDT N/A
- 52 Week Low
- OMH $0.25
- CDT $0.65
- 52 Week High
- OMH $2.70
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- OMH 63.16
- CDT 31.97
- Support Level
- OMH $2.12
- CDT $0.65
- Resistance Level
- OMH $2.31
- CDT $1.05
- Average True Range (ATR)
- OMH 0.22
- CDT 0.14
- MACD
- OMH -0.07
- CDT 0.07
- Stochastic Oscillator
- OMH 23.38
- CDT 7.30
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.